Terray Therapeutics and Gilead Sciences Collaborate on AI-Driven Drug Discovery to Accelerate Small Molecule Therapies

Partnership Overview:
Terray Therapeutics and Gilead Sciences have entered into a strategic collaboration to discover and develop novel small molecule therapies across multiple therapeutic targets identified by Gilead2 3 5.

Technology Platform:
Terray will utilize its tNova platform, which combines high-throughput chemical experimentation and AI-driven drug discovery, to work on targets selected by Gilead2 3 5.

Agreement Terms:
Gilead receives exclusive options to license compounds and will handle further development and commercialization. Terray will receive an upfront payment plus potential milestone payments and tiered royalties on net sales2 3 5.

Impact on Drug Discovery:
The collaboration aims to leverage Terray’s tNova platform to accelerate drug discovery and reduce costs by integrating high-throughput experimentation with generative AI2 3 5.

Terray’s Capabilities:
Terray has built a dataset of over 5 billion target-ligand interaction data points, 50 times larger than all publicly available chemistry data, which will be used to identify novel drug candidates1 4.

Gilead’s Perspective:
Gilead views this partnership as a significant move to enhance its drug discovery capabilities through AI-driven technology, aiming to shape the future of drug discovery across its therapeutic areas of focus2 3 5.